ReForm gets patents for therapeutic protein formulations

By The Science Advisory Board staff writers

April 10, 2020 -- ReForm Biologics has received a U.S. patent for therapeutic protein formulations that reduce protein aggregation and stabilize proteins during storage.

The formulations include a new class of stabilizers to serve as an alternative to traditional surfactants. The company has licensed its ReForm excipients used in biotherapeutic formulations to MilliporeSigma.

ReForm also announced its first patent in Japan for technology to reduce the viscosity of highly concentrated antibody solutions. The excipient technology will enable scientists to more effectively formulate solutions for more preferable delivery routes, the company noted.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.